Navigation Links
BioCryst Pharmaceuticals to Announce Peramivir Update and First Quarter 2009 Financial Results on May 8, 2009
Date:5/7/2009

BIRMINGHAM, Ala., May 7 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals (Nasdaq: BCRX) today announced that an update regarding peramivir and its first quarter 2009 financial results will be released on Friday, May 8, 2009. Following the release, BioCryst will host a conference call and Web cast at 8:30 a.m. Eastern Time to discuss the financial results and provide an update on the Company's programs. The call will be led by Jon P. Stonehouse, President and Chief Executive Officer, Stuart Grant, Chief Financial Officer and Dr. William P. Sheridan, Chief Medical Officer.

The Web cast can be accessed by logging on to http://www.biocryst.com. Please connect to the Web site at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed. To participate in the conference call, please dial 1-800-860-2442 (United States) or 1-412-858-4600 (International). No passcode is needed for the call. The audio portion of the Web cast will be archived and available for replay for 14 days.

About BioCryst

BioCryst is an integrated biopharmaceutical company utilizing crystallography and structure-based drug design to develop a deep pipeline of novel therapeutics targeting major illnesses. BioCryst is currently advancing investigational new drugs discovered in-house in late-stage clinical trials for influenza and lymphoma. In addition, the Company has a pre-clinical portfolio of novel compounds, directed against infectious, cardiovascular, and autoimmune disease targets, to create long-term sustainable value. The Company's strategic alliances with the U.S. Department of Health and Human Services, Shionogi & Co., Ltd., Green Cross Corporation and Mundipharma International Holdings Ltd. validate its scientific foundation and the utility of its product candidates. For more information, please visit the Company's Web site at www.biocryst.com.

BCRXW


'/>"/>
SOURCE BioCryst Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. BioCryst Initiates Enrollment in Pivotal Trial of Forodesine HCL in Patients with Cutaneous T-Cell Lymphoma (CTCL)
2. BioCryst Provides Forodesine HCl Update
3. BioCryst Updates Peramivir Clinical Development Plan
4. BioCryst Announces Initiation of Phase II Study of Intramuscular Peramivir for the Treatment of Seasonal Influenza
5. BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
9. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
10. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
11. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... Nov 30, 2016 Research and Markets has ... Monitoring Devices 2017 - MedCore" report to their offering. ... , , ... the skull. In healthy individuals, it is circulated though the brain and ... where the amount of CSF surrounding the brain changes significantly. ...
(Date:11/30/2016)... Research and Markets has announced the addition of the ... their offering. ... Detachable coil embolization is a minimally invasive method ... embolization treatment of cerebral aneurysms is less invasive and requires less recovery ... wall of an artery in the brain. This area bulges in the ...
(Date:11/30/2016)... Calif. , Nov. 30, 2016 Varian ... it was named America,s Most JUST Company in the ... and Forbes magazine,s inaugural "JUST 100 List." ... of the largest surveys ever conducted on attitudes towards ... months. This inaugural list ranks U.S companies against their ...
Breaking Medicine Technology:
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... ... proudly announces the launch of its 60-day free trial program for all of ... shipping make the offer a truly hassle free experience. , FlexiSpot’s unique desktop ...
(Date:12/2/2016)... ... 02, 2016 , ... With the number of pain management programs available for ... find the one that works for them. When an inventor from Suisun City, Calif., ... and decided to share it with others. , He developed a prototype for PRO ...
(Date:12/2/2016)... ... December 02, 2016 , ... Mediaplanet is proud to ... which covers the innovative treatments, therapeutic technologies, and revolutionized nutrition that are helping ... prolonging life 6 years in the last 3 decades,” says Dr. Valentine Fuster, ...
(Date:12/2/2016)... ... , ... Sourced from the Isbre Springs beneath the 5,000 year old Hardanger ... of just 6 ppm TDS (Total Dissolved Solids) in addition to its excellent taste ... several ShopRite and FoodTown stores in NJ and received rave comments from consumers. , ...
(Date:12/2/2016)... Francisco, CA (PRWEB) , ... December 02, 2016 ... ... digitally-enabled care journeys, announced today that it has raised $6.0 million in an ... inspired by Clarify Health’s conviction that patients and their caregivers can receive far ...
Breaking Medicine News(10 mins):